Glenmark Pharmaceuticals on Wednesday said its auxiliary has gotten endorsement from the US wellbeing controller to advertise Chlorzoxazone tablets, used to treat muscle torment, in the American market.

Glenmark Pharmaceuticals Inc, USA has been conceded last endorsement by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in the quality of 375 mg and 750 mg, the medication producer said in an announcement.

This denotes organization's previously abridged new medication application (ANDA) endorsement out of its new North American assembling office situated in Monroe, North Carolina, it included.

As indicated by IQVIATM deals information, for the year time frame finishing March 2020, the Chlorzoxazone had yearly deals of around $20.9 million.

Snap here to follow LIVE news and updates on financial exchanges

Glenmark's present portfolio currently comprises of 163 items approved for appropriation in the US while 45 ANDAs are pending with the USFDA, the organization said.

Notwithstanding these inward filings, the organization keeps on distinguishing and investigate outside improvement associations to enhance and quicken the development of its current pipeline and portfolio, it included.